500 Intragastric Balloons: What Happens 5 Years Thereafter?
Background The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term we...
Saved in:
| Published in | Obesity surgery Vol. 22; no. 6; pp. 896 - 903 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer-Verlag
01.06.2012
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0960-8923 1708-0428 1708-0428 |
| DOI | 10.1007/s11695-012-0607-2 |
Cover
Loading…
| Abstract | Background
The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term weight loss. The purpose of this study was to present data of 500 obese who, after BIB-induced weight reduction, were followed up for up to 5 years.
Methods
The BioEnterics BIB was used, and remained for 6 months. At 6, 12, and 24 months post-removal (and yearly thereafter), all subjects were contacted for follow-up.
Results
From 500 patients enrolled, 26 were excluded (treatment protocol interruption); 474 thus remained, having initial body weight of 126.16 ± 28.32 kg, BMI of 43.73 ± 8.39 kg/m
2
, and excess weight (EW) of 61.35 ± 25.41. At time of removal, 79 (17%) were excluded as having percent excessive weight loss (EWL) of <20%; the remaining 395 had weight loss of 23.91 ± 9.08 kg (18.73%), BMI reduction of 8.34 ± 3.14 kg/m
2
(18.82%), and percent EWL of 42.34 ± 19.07. At 6 and 12 months, 387 (98%) and 352 (89%) presented with weight loss of 24.14 ± 8.93 and 16.31 ± 7.41 kg, BMI reduction of 8.41 ± 3.10 and 5.67 ± 2.55 kg/m
2
, and percent EWL of 42.73 ± 18.87 and 27.71 ± 13.40, respectively. At 12 and 24 months, 187 (53%) and 96 (27%) of 352 continued to have percent EWL of >20. Finally, 195 of 474 who completed the 60-month follow-up presented weight loss of 7.26 ± 5.41 kg, BMI reduction of 2.53 ± 1.85 kg/m
2
, and percent EWL of 12.97 ± 8.54. At this time, 46 (23%) retained the percent EWL at >20. In general, those who lost 80% of the total weight lost during the first 3 months of treatment succeeded in maintaining a percent EWL of >20 long term after BIB removal: more precisely, this cutoff point was achieved in 83% at the time of removal and in 53%, 27%, and 23% at 12-, 24-, and 60-month follow-up.
Conclusion
BIB seems to be effective for significant weight loss and maintenance for a long period thereafter, under the absolute prerequisite of patient compliance and behavior change from the very early stages of treatment. |
|---|---|
| AbstractList | The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term weight loss. The purpose of this study was to present data of 500 obese who, after BIB-induced weight reduction, were followed up for up to 5 years. The BioEnterics BIB was used, and remained for 6 months. At 6, 12, and 24 months post-removal (and yearly thereafter), all subjects were contacted for follow-up. From 500 patients enrolled, 26 were excluded (treatment protocol interruption); 474 thus remained, having initial body weight of 126.16±28.32 kg, BMI of 43.73±8.39 kg/m^sup 2^, and excess weight (EW) of 61.35±25.41. At time of removal, 79 (17%) were excluded as having percent excessive weight loss (EWL) of <20%; the remaining 395 had weight loss of 23.91±9.08 kg (18.73%), BMI reduction of 8.34±3.14 kg/m^sup 2^ (18.82%), and percent EWL of 42.34±19.07. At 6 and 12 months, 387 (98%) and 352 (89%) presented with weight loss of 24.14±8.93 and 16.31±7.41 kg, BMI reduction of 8.41±3.10 and 5.67±2.55 kg/m^sup 2^, and percent EWL of 42.73±18.87 and 27.71±13.40, respectively. At 12 and 24 months, 187 (53%) and 96 (27%) of 352 continued to have percent EWL of >20. Finally, 195 of 474 who completed the 60-month follow-up presented weight loss of 7.26±5.41 kg, BMI reduction of 2.53±1.85 kg/m^sup 2^, and percent EWL of 12.97±8.54. At this time, 46 (23%) retained the percent EWL at >20. In general, those who lost 80% of the total weight lost during the first 3 months of treatment succeeded in maintaining a percent EWL of >20 long term after BIB removal: more precisely, this cutoff point was achieved in 83% at the time of removal and in 53%, 27%, and 23% at 12-, 24-, and 60-month follow-up. BIB seems to be effective for significant weight loss and maintenance for a long period thereafter, under the absolute prerequisite of patient compliance and behavior change from the very early stages of treatment.[PUBLICATION ABSTRACT] The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term weight loss. The purpose of this study was to present data of 500 obese who, after BIB-induced weight reduction, were followed up for up to 5 years. The BioEnterics BIB was used, and remained for 6 months. At 6, 12, and 24 months post-removal (and yearly thereafter), all subjects were contacted for follow-up. From 500 patients enrolled, 26 were excluded (treatment protocol interruption); 474 thus remained, having initial body weight of 126.16 ± 28.32 kg, BMI of 43.73 ± 8.39 kg/m2, and excess weight (EW) of 61.35 ± 25.41. At time of removal, 79 (17%) were excluded as having percent excessive weight loss (EWL) of <20%; the remaining 395 had weight loss of 23.91 ± 9.08 kg (18.73%), BMI reduction of 8.34 ± 3.14 kg/m2 (18.82%), and percent EWL of 42.34 ± 19.07. At 6 and 12 months, 387 (98%) and 352 (89%) presented with weight loss of 24.14 ± 8.93 and 16.31 ± 7.41 kg, BMI reduction of 8.41 ± 3.10 and 5.67 ± 2.55 kg/m2, and percent EWL of 42.73 ± 18.87 and 27.71 ± 13.40, respectively. At 12 and 24 months, 187 (53%) and 96 (27%) of 352 continued to have percent EWL of >20. Finally, 195 of 474 who completed the 60-month follow-up presented weight loss of 7.26 ± 5.41 kg, BMI reduction of 2.53 ± 1.85 kg/m2, and percent EWL of 12.97 ± 8.54. At this time, 46 (23%) retained the percent EWL at >20. In general, those who lost 80% of the total weight lost during the first 3 months of treatment succeeded in maintaining a percent EWL of >20 long term after BIB removal: more precisely, this cutoff point was achieved in 83% at the time of removal and in 53%, 27%, and 23% at 12-, 24-, and 60-month follow-up. BIB seems to be effective for significant weight loss and maintenance for a long period thereafter, under the absolute prerequisite of patient compliance and behavior change from the very early stages of treatment. The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term weight loss. The purpose of this study was to present data of 500 obese who, after BIB-induced weight reduction, were followed up for up to 5 years.BACKGROUNDThe BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term weight loss. The purpose of this study was to present data of 500 obese who, after BIB-induced weight reduction, were followed up for up to 5 years.The BioEnterics BIB was used, and remained for 6 months. At 6, 12, and 24 months post-removal (and yearly thereafter), all subjects were contacted for follow-up.METHODSThe BioEnterics BIB was used, and remained for 6 months. At 6, 12, and 24 months post-removal (and yearly thereafter), all subjects were contacted for follow-up.From 500 patients enrolled, 26 were excluded (treatment protocol interruption); 474 thus remained, having initial body weight of 126.16 ± 28.32 kg, BMI of 43.73 ± 8.39 kg/m2, and excess weight (EW) of 61.35 ± 25.41. At time of removal, 79 (17%) were excluded as having percent excessive weight loss (EWL) of <20%; the remaining 395 had weight loss of 23.91 ± 9.08 kg (18.73%), BMI reduction of 8.34 ± 3.14 kg/m2 (18.82%), and percent EWL of 42.34 ± 19.07. At 6 and 12 months, 387 (98%) and 352 (89%) presented with weight loss of 24.14 ± 8.93 and 16.31 ± 7.41 kg, BMI reduction of 8.41 ± 3.10 and 5.67 ± 2.55 kg/m2, and percent EWL of 42.73 ± 18.87 and 27.71 ± 13.40, respectively. At 12 and 24 months, 187 (53%) and 96 (27%) of 352 continued to have percent EWL of >20. Finally, 195 of 474 who completed the 60-month follow-up presented weight loss of 7.26 ± 5.41 kg, BMI reduction of 2.53 ± 1.85 kg/m2, and percent EWL of 12.97 ± 8.54. At this time, 46 (23%) retained the percent EWL at >20. In general, those who lost 80% of the total weight lost during the first 3 months of treatment succeeded in maintaining a percent EWL of >20 long term after BIB removal: more precisely, this cutoff point was achieved in 83% at the time of removal and in 53%, 27%, and 23% at 12-, 24-, and 60-month follow-up.RESULTSFrom 500 patients enrolled, 26 were excluded (treatment protocol interruption); 474 thus remained, having initial body weight of 126.16 ± 28.32 kg, BMI of 43.73 ± 8.39 kg/m2, and excess weight (EW) of 61.35 ± 25.41. At time of removal, 79 (17%) were excluded as having percent excessive weight loss (EWL) of <20%; the remaining 395 had weight loss of 23.91 ± 9.08 kg (18.73%), BMI reduction of 8.34 ± 3.14 kg/m2 (18.82%), and percent EWL of 42.34 ± 19.07. At 6 and 12 months, 387 (98%) and 352 (89%) presented with weight loss of 24.14 ± 8.93 and 16.31 ± 7.41 kg, BMI reduction of 8.41 ± 3.10 and 5.67 ± 2.55 kg/m2, and percent EWL of 42.73 ± 18.87 and 27.71 ± 13.40, respectively. At 12 and 24 months, 187 (53%) and 96 (27%) of 352 continued to have percent EWL of >20. Finally, 195 of 474 who completed the 60-month follow-up presented weight loss of 7.26 ± 5.41 kg, BMI reduction of 2.53 ± 1.85 kg/m2, and percent EWL of 12.97 ± 8.54. At this time, 46 (23%) retained the percent EWL at >20. In general, those who lost 80% of the total weight lost during the first 3 months of treatment succeeded in maintaining a percent EWL of >20 long term after BIB removal: more precisely, this cutoff point was achieved in 83% at the time of removal and in 53%, 27%, and 23% at 12-, 24-, and 60-month follow-up.BIB seems to be effective for significant weight loss and maintenance for a long period thereafter, under the absolute prerequisite of patient compliance and behavior change from the very early stages of treatment.CONCLUSIONBIB seems to be effective for significant weight loss and maintenance for a long period thereafter, under the absolute prerequisite of patient compliance and behavior change from the very early stages of treatment. Background The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term weight loss. The purpose of this study was to present data of 500 obese who, after BIB-induced weight reduction, were followed up for up to 5 years. Methods The BioEnterics BIB was used, and remained for 6 months. At 6, 12, and 24 months post-removal (and yearly thereafter), all subjects were contacted for follow-up. Results From 500 patients enrolled, 26 were excluded (treatment protocol interruption); 474 thus remained, having initial body weight of 126.16 ± 28.32 kg, BMI of 43.73 ± 8.39 kg/m 2 , and excess weight (EW) of 61.35 ± 25.41. At time of removal, 79 (17%) were excluded as having percent excessive weight loss (EWL) of <20%; the remaining 395 had weight loss of 23.91 ± 9.08 kg (18.73%), BMI reduction of 8.34 ± 3.14 kg/m 2 (18.82%), and percent EWL of 42.34 ± 19.07. At 6 and 12 months, 387 (98%) and 352 (89%) presented with weight loss of 24.14 ± 8.93 and 16.31 ± 7.41 kg, BMI reduction of 8.41 ± 3.10 and 5.67 ± 2.55 kg/m 2 , and percent EWL of 42.73 ± 18.87 and 27.71 ± 13.40, respectively. At 12 and 24 months, 187 (53%) and 96 (27%) of 352 continued to have percent EWL of >20. Finally, 195 of 474 who completed the 60-month follow-up presented weight loss of 7.26 ± 5.41 kg, BMI reduction of 2.53 ± 1.85 kg/m 2 , and percent EWL of 12.97 ± 8.54. At this time, 46 (23%) retained the percent EWL at >20. In general, those who lost 80% of the total weight lost during the first 3 months of treatment succeeded in maintaining a percent EWL of >20 long term after BIB removal: more precisely, this cutoff point was achieved in 83% at the time of removal and in 53%, 27%, and 23% at 12-, 24-, and 60-month follow-up. Conclusion BIB seems to be effective for significant weight loss and maintenance for a long period thereafter, under the absolute prerequisite of patient compliance and behavior change from the very early stages of treatment. |
| Author | Grosomanidis, Vasilis Kotzampassi, Katerina Papakostas, Pyrros Penna, Sofia Eleftheriadis, Efthymios |
| Author_xml | – sequence: 1 givenname: Katerina surname: Kotzampassi fullname: Kotzampassi, Katerina email: kakothe@yahoo.com organization: Department of Surgery, Aristotle’s University of Thessaloniki – sequence: 2 givenname: Vasilis surname: Grosomanidis fullname: Grosomanidis, Vasilis organization: Department of Surgery, Aristotle’s University of Thessaloniki – sequence: 3 givenname: Pyrros surname: Papakostas fullname: Papakostas, Pyrros organization: Department of Surgery, Aristotle’s University of Thessaloniki – sequence: 4 givenname: Sofia surname: Penna fullname: Penna, Sofia organization: Department of Surgery, Aristotle’s University of Thessaloniki – sequence: 5 givenname: Efthymios surname: Eleftheriadis fullname: Eleftheriadis, Efthymios organization: Department of Surgery, Aristotle’s University of Thessaloniki |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22287051$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kM1KxDAURoMoOqM-gBspuHFTvTdtmkYXouIfDLgZEVfhTuZWK512TDoL394MoyKCrrI5J_lyhmK97VoWYg_hCAH0cUAsjEoBZQoF6FSuiQFqKFPIZbkuBmAKSEsjsy0xDOEVQGIh5abYklKWGhQOxKkCSO7a3tMzhd7XLrmgpum6Npwkjy_UJ7c0n3MbEpU8MfmQjF_YM1U9-7MdsVFRE3j389wWD9dX48vbdHR_c3d5PkpdpmWfZjk50K7KNBKxy7PC5FPMJ9WEJVdKTYkcmrIqGI0rYYI6j3Re6mKqlSaTbYvD1b1z370tOPR2VgfHTUMtd4tgMf7LaKNQR_TgF_raLXwb10UKswLjCBWp_U9qMZnx1M59PSP_br-yRABXgPNdCJ6rbwTBLtPbVXob09tleiujo385ru6pr7tl3Lr515QrM8RX2mf2P0f_JX0A1A6UJQ |
| CitedBy_id | crossref_primary_10_1007_s11695_013_1027_7 crossref_primary_10_1016_j_soard_2017_11_022 crossref_primary_10_1007_s11695_021_05772_5 crossref_primary_10_1016_j_tgie_2016_12_003 crossref_primary_10_1097_MOG_0000000000000561 crossref_primary_10_1016_j_tgie_2016_12_006 crossref_primary_10_1038_ijo_2016_229 crossref_primary_10_1186_s12876_018_0838_3 crossref_primary_10_1016_j_bpg_2014_07_009 crossref_primary_10_1007_s00464_015_4212_z crossref_primary_10_1007_s11695_020_05117_8 crossref_primary_10_1016_j_gie_2015_03_1964 crossref_primary_10_1007_s11695_024_07233_1 crossref_primary_10_1111_den_14994 crossref_primary_10_25000_acem_477680 crossref_primary_10_1016_j_soard_2019_11_012 crossref_primary_10_1007_s11894_016_0501_5 crossref_primary_10_1016_j_gtc_2016_07_008 crossref_primary_10_1007_s10620_017_4566_2 crossref_primary_10_1186_s12893_023_02175_4 crossref_primary_10_1016_j_soard_2019_05_024 crossref_primary_10_1007_s11695_013_0876_4 crossref_primary_10_1586_17474124_2015_965143 crossref_primary_10_1007_s11695_012_0855_1 crossref_primary_10_1007_s11894_020_00798_8 crossref_primary_10_1007_s11695_021_05754_7 crossref_primary_10_2337_ds017_0046 crossref_primary_10_1111_cob_12003 crossref_primary_10_4240_wjgs_v16_i7_2040 crossref_primary_10_3748_wjg_v22_i24_5495 crossref_primary_10_1016_j_ijscr_2020_10_028 crossref_primary_10_1007_s40137_021_00291_9 crossref_primary_10_1053_j_gastro_2017_01_044 crossref_primary_10_3390_polym14112178 crossref_primary_10_1016_j_orcp_2013_07_002 crossref_primary_10_1002_osp4_478 crossref_primary_10_1007_s11695_022_06398_x crossref_primary_10_1007_s11695_021_05530_7 crossref_primary_10_17476_jmbs_2018_7_1_37 crossref_primary_10_1007_s13679_016_0217_8 crossref_primary_10_1111_ases_12025 crossref_primary_10_1016_j_orcp_2015_08_003 crossref_primary_10_1089_lap_2015_0305 crossref_primary_10_1089_bari_2014_0049 crossref_primary_10_1186_s12967_015_0607_9 crossref_primary_10_1007_s11695_019_04075_0 crossref_primary_10_1016_j_cgh_2018_02_026 crossref_primary_10_1177_1553350616643615 crossref_primary_10_1177_2050640620926837 crossref_primary_10_1016_j_soard_2018_07_010 crossref_primary_10_1007_s11695_018_3168_1 crossref_primary_10_1016_j_gie_2015_01_054 crossref_primary_10_3390_life13091905 crossref_primary_10_1016_j_cld_2020_08_001 crossref_primary_10_1089_bari_2016_0010 crossref_primary_10_14309_ajg_0000000000000239 crossref_primary_10_1016_j_soard_2015_12_026 crossref_primary_10_1186_s12876_023_03000_1 crossref_primary_10_1016_j_gie_2016_01_051 crossref_primary_10_1007_s13679_020_00386_x crossref_primary_10_1016_j_gie_2016_02_024 crossref_primary_10_1016_j_giec_2024_06_003 crossref_primary_10_3390_nu14112261 crossref_primary_10_3390_nu14163450 crossref_primary_10_1007_s11695_020_04986_3 crossref_primary_10_1016_j_gie_2015_02_023 crossref_primary_10_1007_s11695_020_04798_5 crossref_primary_10_1007_s13679_018_0307_x crossref_primary_10_17235_reed_2019_4922_2017 crossref_primary_10_1016_j_endoen_2014_04_002 crossref_primary_10_1007_s11695_020_05014_0 crossref_primary_10_7759_cureus_32599 crossref_primary_10_1016_j_soard_2015_12_016 crossref_primary_10_1097_SLE_0000000000001321 crossref_primary_10_1007_s11695_022_06005_z crossref_primary_10_1016_j_endonu_2013_10_011 crossref_primary_10_1159_000518200 crossref_primary_10_1016_j_ejrad_2017_05_019 crossref_primary_10_1111_ases_12881 crossref_primary_10_1016_j_tige_2020_05_002 crossref_primary_10_1007_s13679_024_00551_6 crossref_primary_10_1016_j_tgie_2017_01_001 crossref_primary_10_1016_j_tige_2020_05_001 crossref_primary_10_1007_s11695_016_2459_7 crossref_primary_10_1590_1806_9282_20230571 crossref_primary_10_1016_j_soard_2014_12_006 crossref_primary_10_1097_MOG_0000000000000307 crossref_primary_10_1177_2631774520925647 crossref_primary_10_3390_bs9070072 crossref_primary_10_1007_s11695_020_04644_8 crossref_primary_10_1177_1553350613475881 crossref_primary_10_5946_ce_2017_013 crossref_primary_10_1016_j_soard_2017_12_001 crossref_primary_10_1016_j_soard_2016_02_006 crossref_primary_10_1007_s11695_016_2069_4 crossref_primary_10_1016_S0140_6736_21_02505_8 crossref_primary_10_1007_s11695_022_06089_7 crossref_primary_10_1007_s11695_017_2699_1 crossref_primary_10_1007_s13679_021_00450_0 crossref_primary_10_3748_wjg_v22_i31_7069 crossref_primary_10_3390_healthcare11040600 crossref_primary_10_4103_0366_6999_221283 crossref_primary_10_1089_bari_2022_0047 crossref_primary_10_1007_s10620_018_5117_1 crossref_primary_10_4253_wjge_v13_i8_238 crossref_primary_10_1007_s11906_016_0691_0 crossref_primary_10_3390_nu13124268 crossref_primary_10_5946_ce_2023_253 crossref_primary_10_1089_lap_2013_0439 crossref_primary_10_1007_s11695_016_2458_8 crossref_primary_10_1080_08998280_2018_1559397 |
| Cites_doi | 10.1007/s11695-007-9141-z 10.1007/s11695-010-0127-x 10.1381/0960892052993558 10.1381/096089200321594200 10.1381/0960892041719671 10.1007/s11695-007-9239-3 10.1007/s11695-007-9375-9 10.1111/j.1365-277X.2004.00530.x 10.1016/j.soard.2006.11.001 10.1007/s11695-007-9220-1 10.1007/s11695-010-0093-3 10.1159/000109385 10.1381/096089201321209459 10.1016/j.jada.2007.07.017 10.1016/S0016-5107(87)71611-3 10.1381/0960892054222894 10.1055/s-0029-1214826 10.1002/14651858.CD004931.pub2 10.1007/s11695-007-9331-8 10.1001/jama.282.16.1530 10.1381/09608920160558524 10.1381/096089201321209468 10.1016/S0016-5107(04)02406-X 10.1007/s11695-008-9593-9 10.1007/s11695-008-9766-6 10.1038/oby.2004.151 10.1038/sj.ijo.0803015 10.1007/s11695-009-9879-6 10.1159/000109386 |
| ContentType | Journal Article |
| Copyright | Springer Science + Business Media, LLC 2012 |
| Copyright_xml | – notice: Springer Science + Business Media, LLC 2012 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
| DOI | 10.1007/s11695-012-0607-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Public Health ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Public Health MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1708-0428 |
| EndPage | 903 |
| ExternalDocumentID | 2660863651 22287051 10_1007_s11695_012_0607_2 |
| Genre | Journal Article |
| GeographicLocations | Greece |
| GeographicLocations_xml | – name: Greece |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 1N0 1SB 203 28- 29N 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40D 40E 53G 5RE 5VS 67Z 6NX 7X7 88E 8AO 8C1 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAQQT AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HF~ HG5 HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZQ I~X I~Z J-C J0Z JBSCW JZLTJ KDC KOV KPH LLZTM M1P M4Y MA- N2Q NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJN SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z45 Z7U Z7W Z7X Z82 Z83 Z87 Z8O Z8Q Z8V Z91 Z92 ZMTXR ZOVNA ZXE ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK ABRTQ K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 |
| ID | FETCH-LOGICAL-c372t-34ac07cf371aaec43694d14bfbe2ef55daac198f6e19c80b1747cf4876d757a93 |
| IEDL.DBID | U2A |
| ISSN | 0960-8923 1708-0428 |
| IngestDate | Fri Jul 11 03:08:56 EDT 2025 Sat Jul 26 02:28:13 EDT 2025 Thu Apr 03 07:05:03 EDT 2025 Tue Jul 01 01:31:36 EDT 2025 Thu Apr 24 22:50:09 EDT 2025 Fri Feb 21 02:34:26 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Obesity Excess weight loss Morbid obesity Weight loss Intragastric balloon Follow-up |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c372t-34ac07cf371aaec43694d14bfbe2ef55daac198f6e19c80b1747cf4876d757a93 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| PMID | 22287051 |
| PQID | 1013613715 |
| PQPubID | 55143 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1021979517 proquest_journals_1013613715 pubmed_primary_22287051 crossref_primary_10_1007_s11695_012_0607_2 crossref_citationtrail_10_1007_s11695_012_0607_2 springer_journals_10_1007_s11695_012_0607_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20120600 2012-6-00 2012-Jun 20120601 |
| PublicationDateYYYYMMDD | 2012-06-01 |
| PublicationDate_xml | – month: 6 year: 2012 text: 20120600 |
| PublicationDecade | 2010 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationSubtitle | The Journal of Metabolic Surgery and Allied Care |
| PublicationTitle | Obesity surgery |
| PublicationTitleAbbrev | OBES SURG |
| PublicationTitleAlternate | Obes Surg |
| PublicationYear | 2012 |
| Publisher | Springer-Verlag Springer Nature B.V |
| Publisher_xml | – name: Springer-Verlag – name: Springer Nature B.V |
| References | WaseemTMogensenKMLautzDBPathophysiology of obesity: why surgery remains the most effective treatmentObes Surg200717138913981800073510.1007/s11695-007-9220-1 SpyropoulosCKatsakoulisEMeadNIntragastric balloon for high-risk super-obese patients: a prospective analysis of efficacySurg Obes Relat Dis2007378831724194010.1016/j.soard.2006.11.001 Al-MomenAEl-MogyIIntragastric balloon for obesity: a retrospective evaluation of tolerance and efficacyObes Surg2005151011051576050710.1381/0960892052993558 KotzampassiKShrewsburyADIntragastric balloon: ethics, medical need and cosmeticsDig Dis20082645481860001510.1159/000109386 DastisNSFrançoisEDeviereJIntragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 yearsEndoscopy2009415755801958828310.1055/s-0029-1214826 BaysHECurrent and investigational antiobesity agents and obesity therapeutic treatment targetsObes Res200412119712111534010010.1038/oby.2004.1511:CAS:528:DC%2BD2cXot1Gms7o%3D AllisonDBFontaineKRMansonJEAnnual deaths attributable to obesity in the United StatesJ Am Med Assoc199919992821530153810.1001/jama.282.16.1530 WahlenCHBastensBHerveJThe BioEnterics Intragastric Balloon (BIB): how to use itObes Surg2001115245271150136810.1381/0960892013212094681:STN:280:DC%2BD3MvlsFehsQ%3D%3D CreaNPataGDella CasaDImprovement of metabolic syndrome following intragastric balloon: 1 year follow-up analysisObes Surg200919108410881950698110.1007/s11695-009-9879-6 Fernandes M, Atallah AN, Soares BG, Humberto S, Guimarães S, Matos D, Monteiro L, Richter B. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;(1):CD004931 ImazIMartínez-CervellCGarcía-AlvarezEESafety and effectiveness of the intragastric balloon for obesity. A meta-analysisObes Surg.2008188418461845902510.1007/s11695-007-9331-8 DoldiSBMichelettoGDi PriscoFIntragastric balloon in obese patientsObes Surg2000105785811117596910.1381/0960892003215942001:STN:280:DC%2BD3M7ks1Wiug%3D%3D Mathus-VliegenEMIntragastric balloon treatment for obesity: what does it really offer?Dig Dis20082640441860001410.1159/000109385 MuiWLNgEKTsungBYImpact on obesity-related illnesses and quality of life following intragastric balloonObes Surg201020112811321901593010.1007/s11695-008-9766-6 CurioniCCLourençoPMLong-term weight loss after diet and exercise: a systematic reviewInt J Obes2005291168117410.1038/sj.ijo.08030151:STN:280:DC%2BD2MvotlOrsg%3D%3D National Institutes of HealthClinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of HealthObes Res1998651S209S SalletJAMarchesiniJBPaivaDSBrazilian multicenter study of the intragastric balloonObes Surg2004149919981532919110.1381/0960892041719671 SchapiroMBenjaminSBlackburnGObesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19–21, 1987Gastrointest Endosc198733323327365365310.1016/S0016-5107(87)71611-31:STN:280:DyaL1c%2FgsFKqtg%3D%3D DeitelMHow much weight loss is sufficient to overcome major co-morbidities?Obes Surg2001116591177556010.1381/096089201605585241:STN:280:DC%2BD38%2FkvVWlug%3D%3D Lopez-NavaGRubioMAPradosSBioEnterics® Intragastric Balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloonsObes Surg201121592030615310.1007/s11695-010-0093-3 HerveJWahlenCHSchaekenAWhat becomes of patients one year after the intragastric balloon has been removed?Obes Surg2005158648701597816010.1381/09608920542228941:STN:280:DC%2BD2MzjtVWqtA%3D%3D Mathus-VliegenEMTytgatGNIntragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-upGastrointest Endosc20056119271567205110.1016/S0016-5107(04)02406-X DumonceauJMEvidence-based review of the Bioenterics intragastric balloon for weight lossObes Surg200818161116171856837710.1007/s11695-008-9593-9 Health benefits of weight loss. In: www.maso.org.my/spom/chap4.pdf. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: WHO; 1998 RossiABersaniGRicciGIntragastric balloon insertion increases the frequency of erosive esophagitis in obese patientsObes Surg200717134613491800072410.1007/s11695-007-9239-3 AvenellABrownTJMcGeeMAWhat interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventionsJ Hum Nutr Diet2004172933161525084110.1111/j.1365-277X.2004.00530.x1:STN:280:DC%2BD2czkvV2jsQ%3D%3D MionFGinculRRomanSTolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter studyObes Surg2007177647691787957610.1007/s11695-007-9141-z DumonceauJMFrançoisEHitteletASingle vs repeated treatment with the intragastric balloon: a 5-year weight loss studyObes Surg2010206926972035252410.1007/s11695-010-0127-x FranzMJVanWormerJJCrainALWeight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-upJ Am Diet Assoc2007107175517671790493610.1016/j.jada.2007.07.017 KotzampassiKEleftheriadisEIntragastric balloon as an alterantive procedure for morbid obesityAnn Gastroenterol200619285288 MelissasJIFSO guidelines for safety, quality, and excellence in bariatric surgeryObes Surg2008184975001834050010.1007/s11695-007-9375-9 TottéEHendrickxLPauwelsMWeight reduction by means of intragastric device: experience with the bioenterics intragastric balloonObes Surg2001115195231150136710.1381/096089201321209459 EM Mathus-Vliegen (607_CR20) 2005; 61 WL Mui (607_CR19) 2010; 20 CH Wahlen (607_CR15) 2001; 11 JM Dumonceau (607_CR29) 2008; 18 A Al-Momen (607_CR31) 2005; 15 607_CR1 C Spyropoulos (607_CR24) 2007; 3 T Waseem (607_CR6) 2007; 17 G Lopez-Nava (607_CR27) 2011; 21 607_CR3 607_CR33 607_CR4 NS Dastis (607_CR28) 2009; 41 N Crea (607_CR17) 2009; 19 SB Doldi (607_CR12) 2000; 10 K Kotzampassi (607_CR13) 2008; 26 J Melissas (607_CR14) 2008; 18 I Imaz (607_CR18) 2008; 18 K Kotzampassi (607_CR11) 2006; 19 JA Sallet (607_CR30) 2004; 14 CC Curioni (607_CR9) 2005; 29 A Rossi (607_CR10) 2007; 17 F Mion (607_CR22) 2007; 17 EM Mathus-Vliegen (607_CR25) 2008; 26 J Herve (607_CR21) 2005; 15 M Schapiro (607_CR16) 1987; 33 E Totté (607_CR32) 2001; 11 DB Allison (607_CR2) 1999; 1999 A Avenell (607_CR8) 2004; 17 JM Dumonceau (607_CR26) 2010; 20 HE Bays (607_CR5) 2004; 12 M Deitel (607_CR23) 2001; 11 MJ Franz (607_CR7) 2007; 107 19506981 - Obes Surg. 2009 Aug;19(8):1084-8 11501367 - Obes Surg. 2001 Aug;11(4):519-23 17879576 - Obes Surg. 2007 Jun;17(6):764-9 15760507 - Obes Surg. 2005 Jan;15(1):101-5 15329191 - Obes Surg. 2004 Aug;14(7):991-8 19015930 - Obes Surg. 2010 Aug;20(8):1128-32 17904936 - J Am Diet Assoc. 2007 Oct;107(10):1755-67 18340500 - Obes Surg. 2008 May;18(5):497-500 18000724 - Obes Surg. 2007 Oct;17(10):1346-9 11175969 - Obes Surg. 2000 Dec;10(6):578-81 17241940 - Surg Obes Relat Dis. 2007 Jan-Feb;3(1):78-83 20306153 - Obes Surg. 2011 Jan;21(1):5-9 15925949 - Int J Obes (Lond). 2005 Oct;29(10):1168-74 9813653 - Obes Res. 1998 Sep;6 Suppl 2:51S-209S 19588283 - Endoscopy. 2009 Jul;41(7):575-80 20352524 - Obes Surg. 2010 Jun;20(6):692-7 15672051 - Gastrointest Endosc. 2005 Jan;61(1):19-27 15340100 - Obes Res. 2004 Aug;12(8):1197-211 11501368 - Obes Surg. 2001 Aug;11(4):524-7 18568377 - Obes Surg. 2008 Dec;18(12):1611-7 17253531 - Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004931 18600015 - Dig Dis. 2008;26(1):45-8 15978160 - Obes Surg. 2005 Jun-Jul;15(6):864-70 18000735 - Obes Surg. 2007 Oct;17(10):1389-98 10546692 - JAMA. 1999 Oct 27;282(16):1530-8 3653653 - Gastrointest Endosc. 1987 Aug;33(4):323-7 18600014 - Dig Dis. 2008;26(1):40-4 18459025 - Obes Surg. 2008 Jul;18(7):841-6 15250841 - J Hum Nutr Diet. 2004 Aug;17(4):293-316 11775560 - Obes Surg. 2001 Dec;11(6):659 |
| References_xml | – reference: TottéEHendrickxLPauwelsMWeight reduction by means of intragastric device: experience with the bioenterics intragastric balloonObes Surg2001115195231150136710.1381/096089201321209459 – reference: AvenellABrownTJMcGeeMAWhat interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventionsJ Hum Nutr Diet2004172933161525084110.1111/j.1365-277X.2004.00530.x1:STN:280:DC%2BD2czkvV2jsQ%3D%3D – reference: RossiABersaniGRicciGIntragastric balloon insertion increases the frequency of erosive esophagitis in obese patientsObes Surg200717134613491800072410.1007/s11695-007-9239-3 – reference: WahlenCHBastensBHerveJThe BioEnterics Intragastric Balloon (BIB): how to use itObes Surg2001115245271150136810.1381/0960892013212094681:STN:280:DC%2BD3MvlsFehsQ%3D%3D – reference: MuiWLNgEKTsungBYImpact on obesity-related illnesses and quality of life following intragastric balloonObes Surg201020112811321901593010.1007/s11695-008-9766-6 – reference: MelissasJIFSO guidelines for safety, quality, and excellence in bariatric surgeryObes Surg2008184975001834050010.1007/s11695-007-9375-9 – reference: Al-MomenAEl-MogyIIntragastric balloon for obesity: a retrospective evaluation of tolerance and efficacyObes Surg2005151011051576050710.1381/0960892052993558 – reference: KotzampassiKShrewsburyADIntragastric balloon: ethics, medical need and cosmeticsDig Dis20082645481860001510.1159/000109386 – reference: KotzampassiKEleftheriadisEIntragastric balloon as an alterantive procedure for morbid obesityAnn Gastroenterol200619285288 – reference: WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: WHO; 1998 – reference: CreaNPataGDella CasaDImprovement of metabolic syndrome following intragastric balloon: 1 year follow-up analysisObes Surg200919108410881950698110.1007/s11695-009-9879-6 – reference: Mathus-VliegenEMTytgatGNIntragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-upGastrointest Endosc20056119271567205110.1016/S0016-5107(04)02406-X – reference: DumonceauJMEvidence-based review of the Bioenterics intragastric balloon for weight lossObes Surg200818161116171856837710.1007/s11695-008-9593-9 – reference: Health benefits of weight loss. In: www.maso.org.my/spom/chap4.pdf. – reference: SalletJAMarchesiniJBPaivaDSBrazilian multicenter study of the intragastric balloonObes Surg2004149919981532919110.1381/0960892041719671 – reference: WaseemTMogensenKMLautzDBPathophysiology of obesity: why surgery remains the most effective treatmentObes Surg200717138913981800073510.1007/s11695-007-9220-1 – reference: MionFGinculRRomanSTolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter studyObes Surg2007177647691787957610.1007/s11695-007-9141-z – reference: SpyropoulosCKatsakoulisEMeadNIntragastric balloon for high-risk super-obese patients: a prospective analysis of efficacySurg Obes Relat Dis2007378831724194010.1016/j.soard.2006.11.001 – reference: FranzMJVanWormerJJCrainALWeight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-upJ Am Diet Assoc2007107175517671790493610.1016/j.jada.2007.07.017 – reference: Lopez-NavaGRubioMAPradosSBioEnterics® Intragastric Balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloonsObes Surg201121592030615310.1007/s11695-010-0093-3 – reference: DeitelMHow much weight loss is sufficient to overcome major co-morbidities?Obes Surg2001116591177556010.1381/096089201605585241:STN:280:DC%2BD38%2FkvVWlug%3D%3D – reference: National Institutes of HealthClinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of HealthObes Res1998651S209S – reference: DastisNSFrançoisEDeviereJIntragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 yearsEndoscopy2009415755801958828310.1055/s-0029-1214826 – reference: CurioniCCLourençoPMLong-term weight loss after diet and exercise: a systematic reviewInt J Obes2005291168117410.1038/sj.ijo.08030151:STN:280:DC%2BD2MvotlOrsg%3D%3D – reference: SchapiroMBenjaminSBlackburnGObesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19–21, 1987Gastrointest Endosc198733323327365365310.1016/S0016-5107(87)71611-31:STN:280:DyaL1c%2FgsFKqtg%3D%3D – reference: Mathus-VliegenEMIntragastric balloon treatment for obesity: what does it really offer?Dig Dis20082640441860001410.1159/000109385 – reference: Fernandes M, Atallah AN, Soares BG, Humberto S, Guimarães S, Matos D, Monteiro L, Richter B. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;(1):CD004931 – reference: HerveJWahlenCHSchaekenAWhat becomes of patients one year after the intragastric balloon has been removed?Obes Surg2005158648701597816010.1381/09608920542228941:STN:280:DC%2BD2MzjtVWqtA%3D%3D – reference: AllisonDBFontaineKRMansonJEAnnual deaths attributable to obesity in the United StatesJ Am Med Assoc199919992821530153810.1001/jama.282.16.1530 – reference: DoldiSBMichelettoGDi PriscoFIntragastric balloon in obese patientsObes Surg2000105785811117596910.1381/0960892003215942001:STN:280:DC%2BD3M7ks1Wiug%3D%3D – reference: ImazIMartínez-CervellCGarcía-AlvarezEESafety and effectiveness of the intragastric balloon for obesity. A meta-analysisObes Surg.2008188418461845902510.1007/s11695-007-9331-8 – reference: BaysHECurrent and investigational antiobesity agents and obesity therapeutic treatment targetsObes Res200412119712111534010010.1038/oby.2004.1511:CAS:528:DC%2BD2cXot1Gms7o%3D – reference: DumonceauJMFrançoisEHitteletASingle vs repeated treatment with the intragastric balloon: a 5-year weight loss studyObes Surg2010206926972035252410.1007/s11695-010-0127-x – volume: 17 start-page: 764 year: 2007 ident: 607_CR22 publication-title: Obes Surg doi: 10.1007/s11695-007-9141-z – volume: 20 start-page: 692 year: 2010 ident: 607_CR26 publication-title: Obes Surg doi: 10.1007/s11695-010-0127-x – volume: 15 start-page: 101 year: 2005 ident: 607_CR31 publication-title: Obes Surg doi: 10.1381/0960892052993558 – ident: 607_CR4 – volume: 10 start-page: 578 year: 2000 ident: 607_CR12 publication-title: Obes Surg doi: 10.1381/096089200321594200 – volume: 14 start-page: 991 year: 2004 ident: 607_CR30 publication-title: Obes Surg doi: 10.1381/0960892041719671 – volume: 17 start-page: 1346 year: 2007 ident: 607_CR10 publication-title: Obes Surg doi: 10.1007/s11695-007-9239-3 – volume: 18 start-page: 497 year: 2008 ident: 607_CR14 publication-title: Obes Surg doi: 10.1007/s11695-007-9375-9 – volume: 17 start-page: 293 year: 2004 ident: 607_CR8 publication-title: J Hum Nutr Diet doi: 10.1111/j.1365-277X.2004.00530.x – volume: 3 start-page: 78 year: 2007 ident: 607_CR24 publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2006.11.001 – volume: 17 start-page: 1389 year: 2007 ident: 607_CR6 publication-title: Obes Surg doi: 10.1007/s11695-007-9220-1 – volume: 21 start-page: 5 year: 2011 ident: 607_CR27 publication-title: Obes Surg doi: 10.1007/s11695-010-0093-3 – volume: 26 start-page: 40 year: 2008 ident: 607_CR25 publication-title: Dig Dis doi: 10.1159/000109385 – volume: 11 start-page: 519 year: 2001 ident: 607_CR32 publication-title: Obes Surg doi: 10.1381/096089201321209459 – volume: 107 start-page: 1755 year: 2007 ident: 607_CR7 publication-title: J Am Diet Assoc doi: 10.1016/j.jada.2007.07.017 – volume: 33 start-page: 323 year: 1987 ident: 607_CR16 publication-title: Gastrointest Endosc doi: 10.1016/S0016-5107(87)71611-3 – volume: 15 start-page: 864 year: 2005 ident: 607_CR21 publication-title: Obes Surg doi: 10.1381/0960892054222894 – volume: 41 start-page: 575 year: 2009 ident: 607_CR28 publication-title: Endoscopy doi: 10.1055/s-0029-1214826 – ident: 607_CR1 – ident: 607_CR33 doi: 10.1002/14651858.CD004931.pub2 – volume: 18 start-page: 841 year: 2008 ident: 607_CR18 publication-title: Obes Surg. doi: 10.1007/s11695-007-9331-8 – ident: 607_CR3 – volume: 1999 start-page: 1530 issue: 282 year: 1999 ident: 607_CR2 publication-title: J Am Med Assoc doi: 10.1001/jama.282.16.1530 – volume: 11 start-page: 659 year: 2001 ident: 607_CR23 publication-title: Obes Surg doi: 10.1381/09608920160558524 – volume: 11 start-page: 524 year: 2001 ident: 607_CR15 publication-title: Obes Surg doi: 10.1381/096089201321209468 – volume: 61 start-page: 19 year: 2005 ident: 607_CR20 publication-title: Gastrointest Endosc doi: 10.1016/S0016-5107(04)02406-X – volume: 18 start-page: 1611 year: 2008 ident: 607_CR29 publication-title: Obes Surg doi: 10.1007/s11695-008-9593-9 – volume: 20 start-page: 1128 year: 2010 ident: 607_CR19 publication-title: Obes Surg doi: 10.1007/s11695-008-9766-6 – volume: 19 start-page: 285 year: 2006 ident: 607_CR11 publication-title: Ann Gastroenterol – volume: 12 start-page: 1197 year: 2004 ident: 607_CR5 publication-title: Obes Res doi: 10.1038/oby.2004.151 – volume: 29 start-page: 1168 year: 2005 ident: 607_CR9 publication-title: Int J Obes doi: 10.1038/sj.ijo.0803015 – volume: 19 start-page: 1084 year: 2009 ident: 607_CR17 publication-title: Obes Surg doi: 10.1007/s11695-009-9879-6 – volume: 26 start-page: 45 year: 2008 ident: 607_CR13 publication-title: Dig Dis doi: 10.1159/000109386 – reference: 3653653 - Gastrointest Endosc. 1987 Aug;33(4):323-7 – reference: 15329191 - Obes Surg. 2004 Aug;14(7):991-8 – reference: 18600015 - Dig Dis. 2008;26(1):45-8 – reference: 15340100 - Obes Res. 2004 Aug;12(8):1197-211 – reference: 20352524 - Obes Surg. 2010 Jun;20(6):692-7 – reference: 11501368 - Obes Surg. 2001 Aug;11(4):524-7 – reference: 20306153 - Obes Surg. 2011 Jan;21(1):5-9 – reference: 11175969 - Obes Surg. 2000 Dec;10(6):578-81 – reference: 17904936 - J Am Diet Assoc. 2007 Oct;107(10):1755-67 – reference: 18568377 - Obes Surg. 2008 Dec;18(12):1611-7 – reference: 11775560 - Obes Surg. 2001 Dec;11(6):659 – reference: 18000724 - Obes Surg. 2007 Oct;17(10):1346-9 – reference: 15925949 - Int J Obes (Lond). 2005 Oct;29(10):1168-74 – reference: 18600014 - Dig Dis. 2008;26(1):40-4 – reference: 18340500 - Obes Surg. 2008 May;18(5):497-500 – reference: 15760507 - Obes Surg. 2005 Jan;15(1):101-5 – reference: 17241940 - Surg Obes Relat Dis. 2007 Jan-Feb;3(1):78-83 – reference: 19588283 - Endoscopy. 2009 Jul;41(7):575-80 – reference: 19015930 - Obes Surg. 2010 Aug;20(8):1128-32 – reference: 11501367 - Obes Surg. 2001 Aug;11(4):519-23 – reference: 10546692 - JAMA. 1999 Oct 27;282(16):1530-8 – reference: 18459025 - Obes Surg. 2008 Jul;18(7):841-6 – reference: 15672051 - Gastrointest Endosc. 2005 Jan;61(1):19-27 – reference: 15978160 - Obes Surg. 2005 Jun-Jul;15(6):864-70 – reference: 9813653 - Obes Res. 1998 Sep;6 Suppl 2:51S-209S – reference: 17879576 - Obes Surg. 2007 Jun;17(6):764-9 – reference: 19506981 - Obes Surg. 2009 Aug;19(8):1084-8 – reference: 17253531 - Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004931 – reference: 18000735 - Obes Surg. 2007 Oct;17(10):1389-98 – reference: 15250841 - J Hum Nutr Diet. 2004 Aug;17(4):293-316 |
| SSID | ssj0021622 |
| Score | 2.4104204 |
| Snippet | Background
The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent... The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 896 |
| SubjectTerms | Adolescent Adult Aged Body Mass Index Body Weight Clinical Research Device Removal - methods Female Follow-Up Studies Gastric Balloon - statistics & numerical data Greece - epidemiology Health Behavior Humans Long term Male Medical equipment Medical procedures Medicine Medicine & Public Health Middle Aged Obesity Obesity, Morbid - epidemiology Obesity, Morbid - rehabilitation Obesity, Morbid - surgery Patient Compliance Prospective Studies Surgery Time Factors Treatment Outcome Weight control Young Adult |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDI5gXLggEK_BQEHiBIrUpHm0cJgAMQ0kODFpnKo0TbmgrrDt_2P3sYEmdq7bRrbjfH7EJuQyciLiNsJmeD5m0ocxS5XHsinhjBeAOKrG8y-vejiSz2M1bgJu06assrWJlaHOJg5j5LC7eQhHj-GqX34xnBqF2dVmhMYm2cLWZVjSZcZLh4vrOosAKJ1FgGTarGZ1dY5rvJuMhQk6MEz8PZdWwOZKorQ6fwa7ZKcBjvSulvQe2fDFPrlVQUCfMD77YXEAh6P3mEgHTbqh2JSbDm1ZgqNKFX0HlZ5S0ApAiTgXvH9ARoPHt4cha8YhMBcaMWOhtC4wLgceWOudDHUsMy7TPPXC50pl1joeR7n2PHZRkIKvAdTgkOjMKGPj8JB0iknhjwn1WR7o2ABxLqRyoeXKZCbl1ggnnRNdErTMSFzTKxxHVnwmyy7HyL8E-Jcg_xJ45WrxSlk3ylhH3Gs5nDR7ZposJdwlF4vHoO2YwrCFn8yRBiysAVRouuSolszibxjLMmBjuuS6FdXvj_-zlJP1Szkl26JWEtCVHunMvuf-DGDILD2vdO0HycbUCw priority: 102 providerName: ProQuest |
| Title | 500 Intragastric Balloons: What Happens 5 Years Thereafter? |
| URI | https://link.springer.com/article/10.1007/s11695-012-0607-2 https://www.ncbi.nlm.nih.gov/pubmed/22287051 https://www.proquest.com/docview/1013613715 https://www.proquest.com/docview/1021979517 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEB58gHgR366PJYInpdCkTafVg6yyuiqKiAvrqaRp6kV2F3f9_85s21XxAV7aQydpmXxNvslMZgAOYqtiaWJOhucSL3RB4mXacdiUsugUMY5J4vnbu6jTDa97uled4x7V0e61S3IyU38cdpMRnybmUILIR4_m3XnNpjuBuKtaUytLRqXrgKi5FxN9qV2ZP3XxdTH6xjC_eUcni87FMixVbFG0yuFdgRnXX4WF28ofvgYn2vfFFe_PPhsuwGHFGTvSCUnHgpNyi44ZDslQFVo8EaRHglBBLJHrgp-uQ_ei_Xje8apyCJ4NUI29IDTWR1sEKI1xNgyiJMxlmBWZU67QOjfGyiQuIicTG_sZ2RokTQZJlKNGkwQbMNcf9N0WCJcXfpQgCRcq1DYwUmOOmTSobGitaoBf6yW1Va5wLlnxkn5kOWZVpqTKlFWZUpPDaZNhmSjjL-HdWtlp9c-MONgsIHKBUjdgf_qY0M4uDNN3gzeWoRkWiRViAzbLQZq-jfeykOaYBhzVo_a5818-Zftf0juwqEr4EIp2YW78-ub2iJWMsybMYg_pGp_LJsy3Lp9u2nQ_a9_dPzQnCH0HcGvYvQ |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dS8MwED_EPeiLKH5Np0bQF6XQpE3TKiJ-jc3pEFHQp5qmqS-yTbch_lP-jd6t7VRE33zuJQ2XXy6_yyV3AFuhESHXISXDs5HjWy9yEmnp2pQwygpkHKPE85ftoHHrn9_Juwl4L9_C0LXK0iaODHXaNXRGjqube7j1KC4Pe88OVY2i6GpZQiOHRcu-vaLL1j9onuL8bgtRP7s5aThFVQHHeEoMHM_XxlUmw660tsb3gshPuZ9kiRU2kzLV2qAnngWWRyZ0E6TsKI28PkiVVJqSL6HJr2A7Fw1B5fisfXU9dvF4kMct0C9wQuROZRx19FiPB_Qamq5CBK5yxPed8Ae9_RGaHe149VmYKagqO8qxNQcTtjMP-9J1WZNOhB81lfww7JhC94jdPUZpwFlD93roGjPJ7lFbfYY4RF5KlcgPF-D2X1S1CJOdbscuA7Np5gaRQuFM-NJ4mkuVqoRrJYxvjKiCWyojNkV2ciqS8RR_5lUm_cWov5j0F2OTnXGTXp6a4y_hWqnhuFil_fgTU1XYHH_G9UVBE92x3SHJoE1XyENVFZbymRn_jU7PFFq1KuyWU_W181-GsvL3UDZgqnFzeRFfNNutVZgWOWAQNzWYHLwM7RqSoEGyXiCPwcN_g_0DKC0TWQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS8QwEB5EQbyI4mt11Qh6UYpN2jStIuJr2fWFB4X1VNM09SK7q7si_jV_nTN97CqiN89N0jD5MvkmM5kB2AyNCLkOKRmejRzfepGTSEthU8IoK5Bx5Innr66D5p1_3pbtMfio3sJQWGWlE3NFnXYN3ZHj7uYeHj2Ky92sDIu4OW0c9p4dqiBFntaqnEYBkQv7_obmW_-gdYprvSVE4-z2pOmUFQYc4ykxcDxfG1eZDIfV2hrfCyI_5X6SJVbYTMpUa4NWeRZYHpnQTZC-Y2vk-EGqpNKUiAnV_4TyJKc9ptojY48HhQcDLQQnRBZVeVTzZ3s8oHfRFBQRuMoR38_EH0T3h5M2P_saMzBdklZ2VKBsFsZsZw72peuyFt0NP2oq_mHYMTnxEcV7jBKCs6bu9dBIZpLdo6z6DBGJDJVqkh_Ow92_CGoBxjvdjl0CZtPMDSKFjTPhS-NpLlWqEq6VML4xogZuJYzYlHnKqVzGUzzKsEzyi1F-Mckvxi7bwy69IknHX43rlYTjcr_24xG6arAx_Iw7jdwnumO7r9QGtbtCRqpqsFiszPBvdI-mUL_VYKdaqq-D_zKV5b-nsg6TCPH4snV9sQJTosALwqYO44OXV7uKbGiQrOWwY_Dw3zj_BEliFik |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=500+intragastric+balloons%3A+what+happens+5+years+thereafter%3F&rft.jtitle=Obesity+surgery&rft.au=Kotzampassi%2C+Katerina&rft.au=Grosomanidis%2C+Vasilis&rft.au=Papakostas%2C+Pyrros&rft.au=Penna%2C+Sofia&rft.date=2012-06-01&rft.issn=1708-0428&rft.eissn=1708-0428&rft.volume=22&rft.issue=6&rft.spage=896&rft_id=info:doi/10.1007%2Fs11695-012-0607-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-8923&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-8923&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-8923&client=summon |